COLL

Business Context and Reporting Period

Company: Collegium Pharmaceutical, Inc. (COLL)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Year ended December 31, 2025
Business Overview: Collegium is a biopharmaceutical company focused on ADHD and moderate-to-severe pain management. Its portfolio includes Jornay PM (ADHD), Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (pain), and Symproic (opioid-induced constipation). In September 2024, the company acquired Ironshore Therapeutics, Inc., adding Jornay PM to its portfolio and expanding into neuropsychiatry.

Key Financial Metrics

Note: Total Debt includes $580.0 million in 2025 Term Loan and $241.5 million in 2029 Convertible Notes.

Material Changes vs. Prior Period

• Revenue Growth: Net product revenues increased by $149.2 million (23.6%) to $780.6 million. This was primarily driven by the inclusion of a full year of Jornay PM revenue ($111.7 million increase) following the Ironshore acquisition in September 2024.
• Net Income Decline: Net income decreased by $6.3 million to $62.9 million. Despite higher revenues, this was offset by increased intangible asset amortization ($56.6 million increase due to Ironshore assets), higher selling, general, and administrative (SG&A) expenses ($74.4 million increase), and a $16.0 million loss on debt extinguishment.
• Debt Restructuring: In December 2025, the company entered a new Credit Agreement, issuing a $580.0 million Term Loan to refinance the 2024 Term Loan. This resulted in a $16.0 million loss on extinguishment of debt.
• Generic Competition: In early 2026 (post-period), a third-party generic for Nucynta IR was approved, and Hikma launched an authorized generic version of Nucynta IR. Hikma is expected to launch a generic Nucynta ER in Q1 2026.

Guidance, Outlook, and Risks

• Management Commentary: Management highlighted the successful integration of the Ironshore acquisition and the full-year contribution of Jornay PM. The company maintains a strong liquidity position with $231.3 million in cash and a $100.0 million undrawn revolving credit facility.
• Share Repurchases: The Board authorized a new $150.0 million share repurchase program in July 2025, valid through December 31, 2026. No shares were repurchased under this new program as of year-end.
• Key Risks:
  • Patent Expirations and Generics: Nucynta IR and ER face imminent generic competition in 2026. Xtampza ER faces ongoing patent litigation with Purdue.
  • Regulatory Environment: The company faces scrutiny regarding opioid marketing and abuse-deterrent claims. New FDA labeling requirements for opioids were implemented in July 2025.
  • Debt Obligations: Significant indebtedness ($821.5 million principal) requires substantial cash flow for debt service. The 2025 Term Loan bears variable interest rates (SOFR + spread).
  • Supply Chain: Reliance on sole or limited suppliers for active pharmaceutical ingredients (APIs) and third-party manufacturers creates supply chain risks.

Investor Verification Checklist

• Generic Impact on Nucynta: Verify the actual revenue impact of the Nucynta IR and ER generic launches in 2026, as exclusivity periods expire in late 2025/early 2026.
• Jornay PM Growth Trajectory: Assess whether Jornay PM revenue growth can offset potential declines in the pain portfolio due to generic competition.
• Debt Service Coverage: Confirm the company's ability to service the $580 million variable-rate Term Loan and $241.5 million Convertible Notes amidst potential revenue volatility.
• Patent Litigation Status: Monitor the status of the Purdue litigation regarding Xtampza ER and the new Grünenthal lawsuit regarding Nucynta ER authorized generics.
• Regulatory Compliance: Review any updates on FDA investigations or enforcement actions related to opioid marketing practices or abuse-deterrent labeling claims.